Shilpa Medicare Ltd Half Yearly Results

832.5
(-5.41%)
Dec 12, 2024|01:44:56 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Sept-2024Mar-2024Sept-2023Mar-2023Sept-2022

Gross Sales

636.31

578.45

573.15

526.05

524.06

Excise Duty

0

0

0

0

0

Net Sales

636.31

578.45

573.15

526.05

524.06

Other Operating Income

0

0

0

0

0

Other Income

14.43

10.56

3.74

4.91

12.49

Total Income

650.74

589.01

576.89

530.96

536.55

Total Expenditure

480.61

443.38

468.51

457.42

494.22

PBIDT

170.13

145.64

108.38

73.54

42.33

Interest

49.29

50.43

41.38

35.59

23.06

PBDT

120.84

95.21

67

37.95

19.27

Depreciation

55.39

53.33

54.54

49.77

45.73

Minority Interest Before NP

0

0

0

0

0

Tax

40.87

23.51

21.78

17.33

16.8

Deferred Tax

-7.42

-10.84

-12.07

-14.42

-27.02

Reported Profit After Tax

32.01

29.2

2.75

-14.74

-16.24

Minority Interest After NP

0.01

0.12

-0.04

-0.02

1.58

Net Profit after Minority Interest

32

29.08

2.79

-14.72

-17.81

Extra-ordinary Items

0

6.13

0

0

0

Adjusted Profit After Extra-ordinary item

32

22.95

2.79

-14.72

-17.81

EPS (Unit Curr.)

3.3

3.35

0.32

0

-2.05

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

9.78

8.68

8.68

8.68

8.68

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

26.73

25.17

18.9

13.97

8.07

PBDTM(%)

-

-

-

-

-

PATM(%)

5.03

5.04

0.47

-2.8

-3.09

Shilpa Medicare: Related NEWS

Shilpa Medicare’s JV Oncosol Gets FDA Nod for IMKELDI
28 Nov 2024|12:41 AM

This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.

Read More
Shilpa Medicare Secures Phase III Trial Nod for Recombinant Albumin
26 Nov 2024|07:49 PM

  Shilpa Medicare is the first Indian company to gain approval for Phase III trials of Recombinant Human Albumin.

Read More
Shilpa Medicare Subsidiary Bags European Certification for Nifedipine
19 Nov 2024|05:28 PM

The European Directorate for the Quality of Medicines & Healthcare (EDQM) gave Shilpa Pharma Lifesciences, the company's subsidiary, the Certificate of Suitability (CEP) for Nifedipine.

Read More
Top 10 stocks for today - 4th October, 2024
4 Oct 2024|08:46 AM

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.

Read More
Shilpa Medicare submits new drug application with USFDA
4 Sep 2024|08:59 PM

According to the firm, the NDA submission package is based on three clinical trials, many pre-clinical investigations.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp